Tetra Bio-Pharma

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Tetra Bio-Pharma had revenue of €0 and net profit of -€36.9m

(EUR)	2021	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-36.9m	112.75%
EBITDA	-34.65m	169.98%

Fundamentals

Metric	Value
Market capitalization	€6.76m
Number of shares	423.36m
52-week high/low	€0.0479 - €0.00958
Dividends	No
Beta	2.29
P/E ratio	-0.21
PEG ratio	0.66
P/B ratio	44.69
P/S ratio	0.00

Company profile

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.